Michelle Liane Dean - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Current Oncology (Toronto, Ont.)|May 24, 2024

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line OsimertinibAmanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt, et al.

Clinical Lung Cancer|July 25, 2026

An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non-Small-Cell Lung CancerSiddhartha Goutam, Amanda J W Gibson, Michelle Liane Dean, et al.

Lung Cancer (Amsterdam, Netherlands)|July 29, 2024

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort studySamir H Barghout, Luna Jia Zhan, Starvroula Raptis, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Current Oncology (Toronto, Ont.)|May 24, 2024

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line OsimertinibAmanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt, et al.

Clinical Lung Cancer|July 25, 2026

An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non-Small-Cell Lung CancerSiddhartha Goutam, Amanda J W Gibson, Michelle Liane Dean, et al.

Lung Cancer (Amsterdam, Netherlands)|July 29, 2024

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort studySamir H Barghout, Luna Jia Zhan, Starvroula Raptis, et al.

Pageof 1